We present a new quantitative prostate-specific antigen (PSA) assay using a portable, point-of-care test (PSAwatch) and reader system (BioScan) for measuring PSA concentrations in the range from 0.5 to p25 lg/l. Blood samples from patients (n ¼ 199) were submitted for laboratory PSA and also evaluated using PSAwatch and the BioScan system. PSA concentrations in 188 men were p25 lg/l and studied. Correlation between the two methods was good (R 2 ¼ 0.88) with a standard error of 1.588. The regression line had a bias of À0.02 at the concentration of 4.00 lg/l. This is the first report of a quantitative, portable, point-of-care PSA test and reader system. PSAwatch may reduce the number of hospital visits for patients with prostate disease.
Introduction
Ablin et al. 1 were the first to identify a prostate-specific protein and coin the phrase 'prostate-specific antigen' or PSA. PSA is a 32-kDa single-chain glycoprotein serine protease produced by the secretory epithelium of the prostate gland. Since then, purification of PSA by Wang et al. 2 resulted in PSA becoming the gold standard for the early detection and surveillance of carcinoma of the prostate (CaP). 3 PSA has, in addition, recently been accepted as a tool for surveillance of clinically significant benign prostatic hyperplasia (BPH). 4, 5 The incidence of prostate disease is rising and PSA requests are generating further demand for urology services. It has been estimated that 10-40% of men in their 50s and 60s have at least one PSA test per year, largely in a primary care setting. 6 Active surveillance of early, localized prostate cancer may decrease the number of cases undergoing radical treatment 7 but will, in turn, increase the number of requests for PSA and clinicians outpatient workload.
In England, the number of patients with raised PSA is estimated to have risen by 42% since 1999, but their need for continual surveillance means that this figure is cumulative. 8 At present, samples taken from patients for PSA estimation are generally referred to a centralized hospital laboratory, for analysis on large automated immunoassay analysers. The time taken for return of results is typically 1-3 working days. In the UK, patients usually arrange to be venesected 1-2 weeks before their outpatient appointment in order that the PSA result is ready at their subsequent clinic visit (O Karim, personal communication). By necessity, this process introduces a delay in receiving PSA results and an obligatory repeat or second visit. It is recognized that diagnosis and follow-up of prostate cancer is associated with anxiety relating to fear of disease progression. 9 This delay between venesection and the PSA result being available may therefore, contribute to this psychological stress. In this study, we have investigated a new quantitative, 10 min, PSA assay (PSAwatch, Mediwatch Plc, Rugby, UK) using a portable, point-of-care instrument, the BioScan (Mediwatch Plc, Rugby, UK). The Berkshire Local Research Ethics Committee approved this study.
Materials and methods

Overview of PSAwatch and the BioScan
PSAwatch is intended for the quantitative determination of total PSA in plasma and whole blood in the range from 0.5 to p25 mg/l, although it will measure PSA concentrations down to 0.1 mg/l. PSAwatch comprises of a test strip housed in a plastic cassette. The test strip has three working 'zones', referred to as the application, results and overflow zones. An absorbent blood separation pad lies within the test cassette, beneath the sample application hole, containing 40-nm-diameter colloidal gold particles (gold sol) labelled with monoclonal antibodies directed against PSA ('application zone'). Application of the patient sample to this pad causes the gold sol to be resuspended and, if PSA is present in the sample, to react with the PSA and form a complex.
The pad is in contact with a nitrocellulose membrane, onto which a second anti-PSA monoclonal antibody is immobilized ('test line') in the 'results zone'. This test line, together with a procedural control ('control line'), also in the 'results zone', is visible in a window in the plastic cassette. The patient sample-gold sol mixture moves along the membrane by capillary action, through the 'results zone', and is then absorbed into a porous wicking pad at the end of the nitrocellulose membrane ('overflow zone') ( Figure 1 ).
The formation of a test line in the 'results zone' window indicates the presence of PSA in the patient sample and the intensity of the line relates to the concentration of PSA in that sample. The line is formed as a result of binding of PSA to the gold sol antibody and the subsequent immobilization of this complex, at the 'test line'. The appearance of a second line ('control line') in the window shows the test has been carried out correctly ( Figure 2 ).
The BioScan is a small portable instrument, which is used to measure the intensity of the 'test line'. The intensity of the test line is compared with calibration information specific to the batch of cassettes in use and algorithms within the BioScan reader convert the line intensity into a PSA concentration. For samples with PSA concentrations between 0.1 and p25 mg/l, the PSAwatch -BioScan system delivers a result to one decimal place. If the PSA concentration in a sample is greater than 25 mg/l, the BioScan returns a reading PSA X25 mg/l.
PSA has been shown to form stable complexes with different antiproteases, and the dominating portion of PSA in patient serum occurs in complex with a-1 antichymotrypsin (PSA-ACT). There are, however, large variations in the relation between free PSA and PSA-ACT complex between individuals. The antibodies in the Mediwatch PSAwatch have been selected to give the same molar response (equimolar) to free PSA and PSA-ACT complex within the clinical range of PSA concentration from 0.1 to p25 mg/l. PSAwatch thus gives a true 'total' PSA value independent of the individual variations of free and ACT-complexed PSA.
Patient samples
Male patients (n ¼ 199) were selected randomly from the general urology outpatient population of an NHS district general hospital and a private clinic. All men had been referred for further investigation of a raised PSA, or lower urinary tract symptoms, and PSA measurement was required for further clinical management. All subjects gave informed written consent. Two blood samples were taken simultaneously. One sample was submitted for PSA assay by our standard laboratory method ('third generation PSA' immunometric assay on Immulite 2000 automated analyser (Diagnostic Products Corp., Los Angeles, CA, USA)) for the NHS patients and Roche Elecsys Total PSA' (Roche Diagnostics Corp., Indianapolis, IN, USA) for the private patients. Both laboratory methods have previously been compared with other commercially available PSA assays. 10, 11 The second sample, 5 ml of heparinized blood, was evaluated using the Mediwatch system. A 35 ml aliquot of this heparinized blood was placed in the application hole of the PSAwatch cassette (Figure 3 ). This was followed by 15 ml of buffer solution as per the manufacture's instruc- 
Results
Patient samples
From a total of 199 patients, 11 samples had PSA readings greater than 25 mg/l on laboratory testing and were excluded from the study. The correlation of PSAwatch reading to laboratory result on the remaining 188 samples had an R 2 value of 0.88 with a standard error of 1.588. The linear regression line had a slope of 0.95 and an intercept at 0.15 ( Figure 4 ). This regression line had a bias of À0.02 mg/l at the concentration of 4.00 mg/l. Our impression, from the distribution of the data points around the regression line in Figure 4 , was that the test may be more accurate in the range PSAo10 mg/l. Unfortunately, being random patient samples, there was clustering and the data points were not distributed equally above and below 10 mg/l. Our study was, therefore, not powered to study differences in the accuracy of the test in the range PSAo10 mg/l compared with accuracy in the range PSA410 mg/l. Further clinical studies to answer this question may be indicated.
The actual number of PSA readings obtained from the laboratories or the BioScan reader system, grouped within different PSA ranges (o1.0, 1.0-2.5, 2.51-4.0, 4.01-10.0, 10.01-25.0 and 425.0 mg/l) are shown in Table 1 . A total of 171 samples had PSAo10 mg/l and 17 samples had a PSA410 mg/l.
Discussion
Our results demonstrate that there is good correlation between laboratory measurement of PSA and whole blood assayed for PSA using PSAwatch. Laboratory values for PSA were obtained using a third generation, high-sensitivity assays (analytical sensitivity, 0.003-0.03 mg/l). PSAwatch does not achieve this level of sensitivity, which in clinical practice is only used following radical prostatectomy. PSAwatch should therefore not be used to monitor patients post radical prostatectomy. The sensitivity of the PSAwatch test should, however, be sufficient for the majority of diagnostic and therapeutic clinical indications for PSA measurement. These indications may include PSA surveillance in patients with lower urinary tract symptoms (LUTS), monitoring response of prostate cancer to radiotherapy, brachytherapy or hormone treatment, monitoring PSA relapse following treatment of prostate cancer with radiotherapy, brachytherapy or hormones, PSA measurement in patients with suspicious digital rectal examination (DRE) findings and prostate cancer screening with age-specific ranges.
In the UK, the NHS is facing increasing demands for urological services and it has been suggested that we need new approaches to meet these demands. 13 A range of solutions have been devised to tackle the problem of an increasing clinic workload associated with rising numbers of PSA requests. These solutions include new nurse roles, telephone follow-up for patients with prostate cancer and bespoke computer software. New nurse roles clearly increase capacity in an already An evaluation of PSAwatch O Karim et al overstretched system. Nurse-led telephone follow-up of prostate cancer patients and the PSA tracker software are both innovative solutions to obviate the need of a followup, second visit to receive a PSA result after venesection. 8 Using PSAwatch to measure PSA in clinic would give an immediate PSA result and could potentially help solve the problems associated with the present delay in processing PSA blood samples.
One of the biggest problems facing patients is multiple queuing -patients queue for out patients and then diagnostic tests. In 2002, the Audit Commission described this situation as unacceptable. 14 The goal of the Cancer Services Collaborative 'Improvement Partnership' (CSC) was 'to improve the experience and outcomes for patients with suspected or diagnosed cancer by optimizing core delivery systems across the whole pathway of care'. Pivotal on the CSC checklist for improving cancer access times was 'reducing steps to diagnostics'. 15 PSA readings in patients can be labile and it is recommended that a single raised value be repeated before subjecting a patient to a prostatic biopsy. 16 Measuring PSA in clinic using PSAwatch could, thus, potentially shorten the diagnostic pathway for patients with, or suspected of having, prostate cancer by combining a test with a single hospital or clinic visit.
The 'National tariff' for pathology tests has yet to be published and it will probably be determined in the last quarter of 2007. There are, however, already difficulties deciding how to apportion all the fixed costs of any test in the NHS owing to the different tiers of management and administration. The current estimated NHS price for a PSA test at our own hospital is about d5.06, of which the raw reagent costs are d2.45 (I Walker, personal communication). Mediwatch estimate that the BioScan will be about d1800 and a PSAwatch test will cost between d5 and d6.00 to the end user. Increased efficiency in the diagnostic pathway and an attractive pricing structure, therefore, make this point-of-care PSA test a sensible option in an NHS, which is already facing significant financial constraints.
PSAwatch is, a novel, quantitative, point-of-care PSA assay. PSAwatch has been specifically developed to work with no more than a drop of whole blood (35 ml). The simplicity and convenience of the PSAwatch assay may allow it to be used for those patients in whom an immediate PSA result is desirable. Further clinical trials with this innovative, point-of-care system are encouraged.
